Momenta Pharmaceuticals (MNTA -1.8%) lands on the radar of analysts due to a lush collaboration...

|About: Momenta Pharmaceuticals, ... (MNTA)|By:, SA News Editor

Momenta Pharmaceuticals (MNTA -1.8%) lands on the radar of analysts due to a lush collaboration deal it scored with Baxter and its strategic position in the growing "biosimilars" field. One estimate has the market for biotech generics running as high as $5B over the next few years, with drug offerings from firms such as MNTA and BIIB looking as a cheaper alternatives for strapped health care programs.